- Home
- EQ vs IGI Comparison
EQ vs IGI Comparison
Compare EQ & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- IGI
- Stock Information
- Founded
- EQ 2017
- IGI 2009
- Country
- EQ United States
- IGI United States
- Employees
- EQ N/A
- IGI N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- IGI Investment Managers
- Sector
- EQ Health Care
- IGI Finance
- Exchange
- EQ Nasdaq
- IGI Nasdaq
- Market Cap
- EQ 85.1M
- IGI 102.0M
- IPO Year
- EQ 2018
- IGI N/A
- Fundamental
- Price
- EQ $1.39
- IGI $16.51
- Analyst Decision
- EQ Hold
- IGI
- Analyst Count
- EQ 2
- IGI 0
- Target Price
- EQ $1.00
- IGI N/A
- AVG Volume (30 Days)
- EQ 489.3K
- IGI 33.9K
- Earning Date
- EQ 11-11-2025
- IGI 01-01-0001
- Dividend Yield
- EQ N/A
- IGI 4.79%
- EPS Growth
- EQ N/A
- IGI N/A
- EPS
- EQ N/A
- IGI N/A
- Revenue
- EQ $16,553,000.00
- IGI N/A
- Revenue This Year
- EQ N/A
- IGI N/A
- Revenue Next Year
- EQ N/A
- IGI N/A
- P/E Ratio
- EQ N/A
- IGI N/A
- Revenue Growth
- EQ N/A
- IGI N/A
- 52 Week Low
- EQ $0.27
- IGI $15.13
- 52 Week High
- EQ $2.35
- IGI $17.79
- Technical
- Relative Strength Index (RSI)
- EQ 48.48
- IGI 37.67
- Support Level
- EQ $1.31
- IGI $15.78
- Resistance Level
- EQ $1.58
- IGI $16.87
- Average True Range (ATR)
- EQ 0.13
- IGI 0.20
- MACD
- EQ 0.01
- IGI -0.03
- Stochastic Oscillator
- EQ 48.64
- IGI 63.48
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.